T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer

NCT ID: NCT02073916

Last Updated: 2019-04-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-10-31
• Study Completion Date: 2018-12-31

Brief Summary

This open-label, single-center Phase Ib study will assess the safety and tolerability of combining trastuzumab emtansine (T-DM1) with Lapatinib and Abraxane in patients with metastatic HER2-positive breast cancer.

Detailed Description

This open-label, single-center Phase Ib study will assess the safety and tolerability of combining trastuzumab emtansine (T-DM1) with Lapatinib and Abraxane in patients with metastatic HER2-positive breast cancer. Patients will receive Abraxane on Day 1 of each 1-week cycle and T-DM1 on Day 1 of each 3-week cycle. Patients with take Lapatinib orally daily. Patients will receive the study treatment for 12 weeks.

Conditions

Metastatic Breast Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

T-DM1 + Lapatinib + Abraxane

T-DM1 with Laptinib followed by Abraxane

Group Type: EXPERIMENTAL

T-DM1

Intervention Type: DRUG

antibody-drug conjugate of trastuzumab and emtansine

Lapatinib

Intervention Type: DRUG

Dual tyrosine kinase inhibitor (HER2 and EGFR)

Abraxane

Intervention Type: DRUG

albumin-bound paclitaxel. Chemotherapy - microtubule inhibitor

Interventions

T-DM1

antibody-drug conjugate of trastuzumab and emtansine

Intervention Type: DRUG

Lapatinib

Dual tyrosine kinase inhibitor (HER2 and EGFR)

Intervention Type: DRUG

Abraxane

albumin-bound paclitaxel. Chemotherapy - microtubule inhibitor

Intervention Type: DRUG

Other Intervention Names

Trastuzumab Emtansine; TE; Kadcyla; Tykerb; nab-paclitaxel

Eligibility Criteria

Inclusion Criteria

• Documented metastatic Her2 over-expressed breast cancer.
• Age ≥ 18 years Patients must have received at least two prior therapies for their malignant disease.
• Patients must have < Grade 2 pre-existing peripheral neuropathy (per CTCAE)
• Adequate organ function (cardiac ejection fraction of ≥ 45%),
• CBC not less than .75 of institutional lower limit.
• Patients must have adequate liver function: AST and ALT < 2.5 X upper limit of normal, alkaline phosphatase < 2.5 X upper limit of normal, unless bone metastasis is present in the absence of liver metastasis Bilirubin < 1.5 mg/dL
• Patients must have adequate renal function: creatinine <1.5 mg/dL is recommended; however, institutional norms are acceptable.
• Negative serum or urine β-hCG pregnancy test at screening for patients of childbearing potential
• Fertile patients must use effective contraception (barrier method - condoms, diaphragm - also in conjunction with spermicidal jelly, or total abstinence. Oral, injectable, or implant hormonal contraceptives are not allowed). Contraception method must be used during treatment and for three months after completing treatment Signed informed consent form (ICF)

Exclusion Criteria

• Any medical or psychiatric condition that would prevent informed consent or limit survival to less than 4 weeks.
• Absolute QT interval of >460 msec in the presence of potassium >4.0mEq/L and Magnesium >1.8mg/dl.
• Patient with HIV and post- transplant associated lymphoproliferative disorders.
• Patient with concurrent use of complementary or alternative medicines that would confound the interpretation of toxicities and antitumor activity of Trastuzumab Emtansine, Lapatinib or Abraxane.
• Pregnant or lactating women.
• Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial
• Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trastuzumab Emtansine, lapatinib, abraxane, or their components.
• Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel.
• Subjects with ulcerative colitis are also excluded.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

The Methodist Hospital Research Institute

OTHER

Sponsor Role: collaborator

Jenny C. Chang, MD

OTHER

Sponsor Role: lead

Responsible Party

Jenny C. Chang, MD

Sponsor-Investigator/Principal Investigator

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Jenny C Chang, MD

Role: PRINCIPAL_INVESTIGATOR

The Methodist Hospital Research Institute

Locations

Houston Methodist Hospital

Houston, Texas, United States

Countries

United States

Other Identifiers

0813-0139

Identifier Type: OTHER

Identifier Source: secondary_id

Pro00009544

Identifier Type: -

Identifier Source: org_study_id